Selected article for: "activity risk and acute respiratory"
Author: Sanidas, Elias; Grassos, Charalampos; Papadopoulos, Dimitrios; Velliou, Maria; Barbetseas, John
Title: Pulmonary Embolism Prophylaxis in Patients with COVID-19: An Emerging Issue
  • Cord-id: mshd6xef
  • Document date: 2021_5_12
    • ID: mshd6xef
    Snippet: Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected dise
    Document: Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected disease. This review summarises current aspects and recommendations regarding the use of thromboprophylaxis for PE in patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest imaging and admission prior: 1
    • abnormal chest imaging and lung infiltrate: 1
    • abnormal chest imaging and lung injury: 1
    • acquire syndrome and acute respiratory syndrome: 1, 2, 3, 4, 5
    • activator inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • activator inhibitor and lmwh low molecular weight heparin: 1
    • activator inhibitor and low molecular: 1, 2
    • activator inhibitor and low molecular weight: 1, 2
    • activator inhibitor and low molecular weight heparin: 1, 2
    • activator inhibitor and lung injury: 1, 2, 3, 4, 5, 6
    • active cancer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • active cancer and admission prior: 1, 2, 3
    • active cancer and lopinavir ritonavir: 1, 2, 3
    • active cancer and low incidence: 1, 2